Driscoll JP - Search Results

1

In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin.

Grillo MP, Erve JCL, Dick R, Driscoll JP, Haste N, Markova S, Brun P, Carlson TJ, Evanchik M. Grillo MP, et al. Among authors: driscoll jp. Xenobiotica. 2019 Jun;49(6):718-733. doi: 10.1080/00498254.2018.1495856. Epub 2018 Oct 1. Xenobiotica. 2019. PMID: 30044681

2

Preclinical in vitro and in vivo pharmacokinetic properties of danicamtiv, a new targeted myosin activator for the treatment of dilated cardiomyopathy.

Grillo MP, Markova S, Evanchik M, Trellu M, Moliner P, Brun P, Perreard-Dumaine A, Vicat P, Driscoll JP, Carlson TJ. Grillo MP, et al. Among authors: driscoll jp. Xenobiotica. 2021 Feb;51(2):222-238. doi: 10.1080/00498254.2020.1839982. Epub 2020 Nov 16. Xenobiotica. 2021. PMID: 33078965

3

Metabolite Profiling and Reaction Phenotyping for the in Vitro Assessment of the Bioactivation of Bromfenac †.

Yadav AS, Shah NR, Carlson TJ, Driscoll JP. Yadav AS, et al. Among authors: driscoll jp. Chem Res Toxicol. 2020 Jan 21;33(1):249-257. doi: 10.1021/acs.chemrestox.9b00268. Epub 2019 Dec 23. Chem Res Toxicol. 2020. PMID: 31815452

4

Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species.

Choo EF, Driscoll JP, Feng J, Liederer B, Plise E, Randolph N, Shin Y, Wong S, Ran Y. Choo EF, et al. Among authors: driscoll jp. Xenobiotica. 2009 Sep;39(9):700-9. doi: 10.1080/00498250902991827. Xenobiotica. 2009. PMID: 19552528

5

Biotransformation and bioactivation reactions of alicyclic amines in drug molecules.

Bolleddula J, DeMent K, Driscoll JP, Worboys P, Brassil PJ, Bourdet DL. Bolleddula J, et al. Among authors: driscoll jp. Drug Metab Rev. 2014 Aug;46(3):379-419. doi: 10.3109/03602532.2014.924962. Epub 2014 Jun 9. Drug Metab Rev. 2014. PMID: 24909234 Review.

6

Elucidating the Mechanism of Tofacitinib Oxidative Decyanation.

Le H, Fan PW, Wong S, Ma S, Driscoll JP, Hop CE, Cyrus Khojasteh S. Le H, et al. Among authors: driscoll jp. Drug Metab Lett. 2016;10(2):136-43. doi: 10.2174/1872312810666160427104954. Drug Metab Lett. 2016. PMID: 27117606

7

Inhibitory Effects of Trapping Agents of Sulfur Drug Reactive Intermediates against Major Human Cytochrome P450 Isoforms.

Sodhi JK, Delarosa EM, Halladay JS, Driscoll JP, Mulder T, Dansette PM, Khojasteh SC. Sodhi JK, et al. Among authors: driscoll jp. Int J Mol Sci. 2017 Jul 20;18(7):1553. doi: 10.3390/ijms18071553. Int J Mol Sci. 2017. PMID: 28726718 Free PMC article.

8

Bioactivation and reactivity research advances - 2021 year in review.

Jackson KD, Argikar UA, Cho S, Crouch RD, Driscoll JP, Heck CJS, King L, Maw HH, Miller GP, Seneviratne HK, Wang S, Wei C, Zhang D, Khojasteh SC. Jackson KD, et al. Among authors: driscoll jp. Drug Metab Rev. 2022 Aug;54(3):246-281. doi: 10.1080/03602532.2022.2097254. Epub 2022 Aug 5. Drug Metab Rev. 2022. PMID: 35876116 Free PMC article. Review.

9

Role of Glucuronidation and P450 Oxidation in the Bioactivation of Bromfenac.

Driscoll JP, Yadav AS, Shah NR. Driscoll JP, et al. Chem Res Toxicol. 2018 Apr 16;31(4):223-230. doi: 10.1021/acs.chemrestox.7b00293. Epub 2018 Apr 2. Chem Res Toxicol. 2018. PMID: 29569911

10

Going Beyond Common Drug Metabolizing Enzymes: Case Studies of Biotransformation Involving Aldehyde Oxidase, γ-Glutamyl Transpeptidase, Cathepsin B, Flavin-Containing Monooxygenase, and ADP-Ribosyltransferase.

Fan PW, Zhang D, Halladay JS, Driscoll JP, Khojasteh SC. Fan PW, et al. Among authors: driscoll jp. Drug Metab Dispos. 2016 Aug;44(8):1253-61. doi: 10.1124/dmd.116.070169. Epub 2016 Apr 26. Drug Metab Dispos. 2016. PMID: 27117704 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30 results

Search Page

Filters